Most reports of chronic GVHD after cord blood transplantation (CBT) have utilized traditional diagnostic criteria. We used traditional criteria and National Institutes of Health (NIH) criteria prospectively to evaluate chronic GVHD in a cohort of 87 adult and pediatric recipients of single or double unrelated CBT for treatment of hematologic malignancies. Fifty-four patients developed traditionally defined chronic GVHD, for an estimated 2-year probability of 64%. Among 54 patients, 25 (46%) met the NIH criteria for persistent, recurrent or late acute GVHD at onset. Twenty-four (44%) had overlap chronic GVHD, including one who presented initially with late acute GVHD, and only seven (13%) had classic chronic GVHD, including one who also presented initially with late acute GVHD. Among patients who successfully discontinued all systemic immunosuppression (SI), the median time to discontinuation of corticosteroid treatment was 315 days (range 28-977), and the median time to discontinuation of all SI was 353 days (range 67-977). Chronic GVHD diagnosed by traditional criteria after CBT had a predominance of acute GVHD clinical features.
INTRODUCTION
Unrelated cord blood (CB) is increasingly being used as an alternative stem cell source for hematopoietic cell transplantation in both adults and children. Less stringent HLA-matching requirements with CB transplantation (CBT) allow 495% of patients to find at least one 4/6-HLA-matched CB unit suitable for SCT (http://www.marrow.org/PHYSICIAN/URD_Search_and_Tx/ Likelihood_of_Finding_an_URD_o/index.html). Most adult and larger adolescent patients receive two highly mismatched CB units in order to overcome the limited cell dose available from single CB grafts and to reduce the problem of delayed engraftment. 1 Although an increased incidence of acute GVHD after double-unit CBT (dCBT) compared with single CBT has been described, 2 a lower incidence of chronic extensive GVHD has been reported after CBT compared with other stem cell sources, [3] [4] [5] albeit with wide ranges from 10 to 89% described after single and dCBTs. [6] [7] [8] [9] [10] [11] [12] Most of the chronic GVHD outcomes reported after CBT were captured using the traditional clinical diagnostic criteria and mostly registry data in the few large studies. [7] [8] [9] [10] [11] [12] [13] Chronic GVHD outcomes using the 2005 National Institutes of Health (NIH) consensus criteria 14 have been evaluated in several studies after BM and mobilized peripheral blood (PB) SCT (BMT and PBSCT), [15] [16] [17] [18] but only limited data have been reported for chronic GVHD after CBT. We conducted a single-center study to evaluate the incidence of chronic GVHD after CBT according to both the traditional diagnosis and the NIH chronic GVHD consensus criteria captured prospectively at our center. The analysis included a comprehensive review of the clinical features and course of chronic GVHD after CBT in order to determine the prevalence of clinical manifestations, duration of immunosuppression and need for subsequent treatment for control of GVHD. In addition, we analyzed potential risk factors for the development of chronic GVHD.
We also wanted to describe the prevalence of clinical manifestations according to the NIH chronic GVHD criteria and to evaluate the duration of systemic immunosuppressive therapy after CBT, in order to enable a comparison with results reported after BMT or PBSCT at our center. 15, 19, 20 
PATIENTS AND METHODS
This single-center, prospective study included 87 consecutive adult and pediatric patients with malignant diseases who received a first CBT as part of a clinical trial at our center between 2006 and 2011. Patients who had received any prior allogeneic transplant were excluded. All patients received cyclosporine plus mycophenolate mofetil for prevention of acute GVHD, and most patients received a dCBT with a high-intensity conditioning regimen. All patients or their parents signed informed consent approved by the Fred Hutchinson Cancer Research Center Institutional Review Board before CBT, which also allowed for collection of information related to major events after transplantation including acute and chronic GVHD. Follow-up clinical information was available from medical records submitted by referring physicians and from documentation generated by a dedicated long-term follow-up clinical program.
Definitions GVHD in our study was defined when clinical manifestations were treated with systemic therapy. Acute GVHD was graded according to previously described criteria. 21 Endoscopic biopsies were used to establish the diagnosis of grade-II GVHD in patients with isolated upper gastrointestinal tract symptoms such as anorexia, nausea and emesis. 22 All patients were screened for evidence of chronic GVHD between days 80 and 100 after CBT, at 1-year after transplantation, and whenever clinically indicated to establish the diagnosis of chronic GVHD or to determine treatment. Chronic GVHD requiring systemic immunosuppression (SI) was diagnosed by both traditional criteria 23, 24 and by the 2005 NIH Consensus Criteria for Clinical Trials in chronic GVHD.
14 In brief, the NIH consensus recognizes two 1 main categories of GVHD, each with two subtypes. The broad category of acute GVHD includes classic acute GVHD (maculopapular erythematous rash, gastrointestinal symptoms or cholestatic hepatitis), occurring within 100 days after hematopoietic cell transplantation, and also persistent, recurrent or late-onset acute GVHD, occurring 4100 days after transplantation. For brevity, the latter subtype is henceforth designated in the article as 'late acute' GVHD. The presence of GVHD without diagnostic or distinctive chronic GVHD manifestations defines the broad category of acute GVHD. The broad category of NIH chronic GVHD includes classic chronic GVHD, presenting with manifestations that can be ascribed only to chronic GVHD, and includes an overlap subtype, which has diagnostic or distinctive chronic GVHD manifestations together with features typical of acute GVHD. The number of successive treatment cycles needed to control chronic GVHD was determined as previously described. 19 
Statistical analysis
Cumulative incidence estimates were used to summarize the probability of each type of GVHD. Death without GVHD was regarded as a competing risk for GVHD. Cox regression was used to assess the association of various factors with the risk of chronic GVHD.
RESULTS

Patient and donor characteristics
Patient, donor and transplantation characteristics are summarized in Table 1 . The median patient age at time of CBT was 31 years (range 0.8-70.8) and 51% were male. Most patients received a high-intensity conditioning regimen (n ¼ 69, 79%). All patients had a hematological malignancy, and the most frequent diagnosis was AML (56%). Most patients received two CB units (n ¼ 75, 86%). Eleven patients received unmanipulated CB grafts together with ex vivo expanded CB units as previously described. 25 Most patients received 4/6-matched CB units (59%), and only 4% received 6/6-matched units.
GVHD
Acute GVHD. Figure 1a shows the estimated probability of grades II-IV acute GVHD after CBT diagnosed before day 100. Of the 87 patients, 65 (75%) developed grades II-IV acute GVHD and 26 (30%) developed grades III-IV acute GVHD. One patient had grade IV acute GVHD. Among those who developed grades II-IV acute GVHD, the median time to diagnosis was 19 days (range 6-79) after CBT (Table 2 ).
Chronic GVHD. Of the 87 patients, 68 were alive, free of malignancy and engrafted with donor cells between 80 and 100 days after transplantation. Fifty-four patients were diagnosed with chronic GVHD by traditional criteria with onset at a median of 4.1 months (range 2.6-20) after CBT, and reaching an estimated cumulative incidence of 64% at 2 years ( Figure 1b) . Most patients had quiescent onset of chronic GVHD (n ¼ 37, 69%) and 26 patients (48%) had thrombocytopenia at the onset of chronic GVHD (Table 2) .
Of the 54 patients who developed chronic GVHD by the traditional criteria, 25 patients presented with NIH-defined persistent (n ¼ 3), recurrent (n ¼ 20) or late (n ¼ 20) acute GVHD manifestations (for brevity referred thereafter as 'late acute'), reaching an estimated cumulative incidence of 30% at 2 years ( Figure 1b) . In all, 2 of the 25 patients with 'late acute' GVHD subsequently developed NIH chronic GVHD.
In total, 31 of the 54 patients with traditionally defined chronic GVHD met the NIH chronic GVHD criteria (Table 3) , reaching an estimated cumulative incidence of 37% at 2 years after CBT (Figure 1b ). Most patients (n ¼ 24) with NIH chronic GVHD presented with overlap subtype at a median of 113 days after transplantation (range 80-412), including one patient with 'late acute' gut and skin GVHD on day 120 who later developed overlap chronic GVHD with acute gut and skin involvement and chronic oral features at day 365. Seven patients met the NIH-defined subtype of 'classic' chronic GVHD at a median of 121 days after transplantation (range 91-241), including one patient with 'late acute' skin GVHD at day 184 who subsequently developed classic chronic GVHD with skin involvement at day 363.
Manifestations of any chronic GVHD at any time and according to NIH subtypes are shown in Figure 2 . The most common organ affected by chronic GVHD at any time was the gastrointestinal tract, occurring in 17 patients presenting with 'late acute' GVHD For recipients of multiple cord blood units, the number of Ag matches reflects the least matched unit.
Chronic GVHD after cord blood transplantation LF Newell et al and in 22 with overlap chronic GVHD. One patient with overlap chronic GVHD was also diagnosed with Evan's syndrome. In all, 2 of the 54 patients diagnosed with chronic GVHD by traditional criteria did not meet NIH criteria for either 'late acute' or chronic GVHD. One patient was diagnosed with cryptogenic organizing pneumonia at day 123, and the other developed anasarca at day 309. Both patients received systemic immunosuppressive treatment.
Duration of steroid therapy and immunosuppression. Figure 3 shows the estimated cumulative incidence of discontinuation of all SI. Among the 54 patients, 18 successfully discontinued all systemic treatment at 67-977 days (median 353) after the initial diagnosis of any chronic GVHD. The median duration of corticosteroid treatment among these 18 patients was 315 days (range 28-977). Patients presented with 'late acute' GVHD discontinued immunosuppression at a median of 403 days (range 67-695) after diagnosis, compared with a median of 309 days (range 127-977) for patients with overlap chronic GHVD subtype. Among the 36 patients who had not discontinued all systemic treatment at the time of last contact, 21 were alive at a median 247 days from the initial diagnosis of chronic GVHD (range 0-1349), and 15 had died at a median of 106 days after the diagnosis of chronic GVHD (range 26-974).
By NIH criteria, patients with any 'late acute' GVHD received a median of one treatment cycle (range 1-5), those with overlap chronic GVHD received a median of two treatment cycles (range 1-4) and those with the classic subtype of chronic GVHD received a median of one treatment cycle (range 1-2). Treating number of treatment cycles as a continuous variable, the average number in the group with overlap subtype was not statistically significantly larger than that among the other two groups (P ¼ 0.13).
Chronic GVHD features associated with severe morbidity. Among the 54 patients with any chronic GVHD by traditional criteria after CBT, 8 (15%) developed clinical features associated with severe morbidity. The severe manifestations included serosal involvement (pericardial and/or pleural effusions) in five patients, bronchiolitis obliterans in two and esophageal stricture in one. No patient developed sclerotic features or joint contractures related to chronic GVHD (Table 3) .
Causes of death. In all, 16 of the 54 patients diagnosed with any chronic GVHD died at a median of 223 days after CBT (range 133-1106). Causes of death included recurrent malignancy (n ¼ 6), multi-system organ failure (n ¼ 5), infections (n ¼ 3) and chronic GVHD in two cases (that is, bronchiolitis obliterans at day 144, and gut GVHD at day 156).
Risk factors for the development of chronic GVHD. We analyzed possible risk factors for the development of any chronic GVHD Platelet count unavailable for one patient after dCBT, and for two patients after single CBT.
Chronic GVHD after cord blood transplantation LF Newell et al after CBT, including patient characteristics, conditioning intensity, dose of TBI, infused cell doses (Total nucleated cells, CD34 þ and CD3 þ /kg), number of CB units and HLA-match, and history of acute GVHD. There were no factors that showed a statistically significant association with the risk of chronic GVHD.
DISCUSSION
The 64% 2-year cumulative incidence of any chronic GVHD after CBT by traditional criteria in this study is higher than the 10-40% range previously reported in most studies of CBT (Supplementary Materials, Supplementary Table S1) . [6] [7] [8] [9] [10] [11] [12] [13] 26 Our results, however, are similar to the rates of chronic GVHD reported after better HLA-matched-related and -unrelated donor BMT or PBSCT at our center. 27 Most CBT patients diagnosed with traditionally defined chronic GVHD presented by NIH criteria with either 'late acute' GVHD or the overlap subtype of chronic GVHD. Moreover, most patients with 'late acute' GVHD never subsequently developed NIH chronic GVHD.
The wide variability in rates of chronic GVHD after CBT previously reported may be explained by several factors such as the criteria used to establish the diagnosis, type of GVHD One patient with cryptogenic organizing pneumonia at day 123 posttransplant, and another patient with anasarca at day 309 after transplant, both events were attributed to GVHD and treated with systemic immunosuppression.
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Sites of any chronic GVHD Sites of "late acute" GVHD Figure 2 . Sites of chronic GVHD at any time and according to the NIH categories. The gastrointestinal tract was the most common site in patients with any chronic GVHD, 'late acute' GVHD and overlap subtype of chronic GVHD. The classic subtype of chronic GVHD predominately involved the mouth and skin. 
Probability
Years after cGVHD diagnosis Figure 3 . Probability of discontinuation of immunosuppression for chronic GVHD. Among the 54 patients with any chronic GVHD, 18 successfully discontinued all immunosuppression. Of the patients unable to discontinue immunosuppression, 21 were alive without relapse and 15 died while on immunosuppression.
prophylaxis used, patient age, number of CB units and cell doses infused, and the use of registry or retrospective data to capture chronic GVHD. The high incidence of chronic GVHD in this study and also in other studies from our center may be related to our standard practice of systematically screening for chronic GVHD in all patients between days 80 and 100 after allogeneic hematopoietic cell transplantation and again at 1 year, and by diligently providing telemedicine assistance to patients and their primary physicians about the diagnosis and management of chronic GVHD whenever new clinical manifestations appear. Moreover, we systematically capture all data on 'late acute' and chronic GVHD by using NIH assessment tools in our long-term follow-up program. At the time of initial symptoms of GVHD, we actively pursue tissue diagnosis with a high frequency of both upper and lower endoscopy as well as skin biopsies. The high incidence of both acute and chronic GVHD and the 30% incidence of grades III-IV acute GVHD in our study may also be related to certain characteristics of the study population. For example, most patients received double CB grafts, which carry an increased risk of acute GVHD as compared with single CB grafts. 2 In addition, the median age of the patients in our cohort was higher than the age of patients in previous CBT studies. 6, 8, 13 In our study, approximately 90% of GVHD developing 4100 days after CBT manifested as 'late acute' GVHD or as overlap chronic GVHD by NIH criteria, especially with involvement of the gastrointestinal tract. Although this finding is consistent with a prior report evaluating NIH chronic GVHD after CBT, 26 most but not all 15 prior analyses of NIH chronic GVHD after BMT and PBSCT reported low rates of 'late acute' GVHD (Supplementary Materials, Supplementary Table S2) . [16] [17] [18] 28 The numbers of patients within the NIH chronic GVHD subtypes were too small to permit further analysis of overall survival and non-relapse mortality according to these subtypes.
The median time to end of corticosteroid treatment and all other SI was 11.5 months (range 2.2-32) after the initial diagnosis of any chronic GVHD among the 18 patients who successfully discontinued immunosuppression. The small size of the CBT cohort did not permit formal comparative analysis with the duration of SI after other graft sources. We note, however, that the previously reported median duration of systemic treatment from time of onset of any chronic GVHD after BMT or PBSCT, among 348 patients at our center who discontinued immunosuppressive therapy, was 28.7 months (range 0.9-115) among the 235 patients with NIH chronic GVHD, and 15.6 months (range 2-112) among the 113 patients with 'late acute' GVHD without NIH chronic. 15 In another analysis of 751 patients with chronic GVHD after BMT or PBSCT diagnosed by traditional criteria, the median duration of SI was 23 months among the 274 patients who discontinued immunosuppressive therapy. 20 Taking all these data together, the duration of SI for control of chronic GVHD may be shorter after CBT. This suggestion should be taken with caution, given the small sample size, shorter duration of follow-up in our cohort, and lack of formal comparative analysis of other graft sources and risk factors for this outcome.
To our knowledge, only one prior analysis has evaluated GVHD after CBT according to the 2005 NIH consensus criteria. This study included only pediatric patients who received a single CB unit, 26 whereas our cohort included both adults and children who received either single or dCBT. In the prior study of 79 children, the cumulative incidence of grades II-IV and III-IV acute GVHD at day 100 was 42% and 22%. These rates were lower than the 75% and 30% rates, respectively, observed in our study. The cumulative incidence of any chronic GVHD was also lower at 27%. In our study, GVHD prophylaxis consisted of cyclosporine and mycophenolate mofetil in all cases, and equine anti-thymocyte globulin was given to only 5 of the 18 patients who were treated with reduced-intensity conditioning regimens. In the prior study, all patients received either equine anti-thymocyte globulin or alemtuzumab. Similar to our findings, the results of this prior study showed a predominance of 'late acute' GVHD (71%) and overlap chronic GVHD (24%).
The mechanisms for the predominance of acute GVHD features in patients with GVHD requiring systemic treatment 4100 days after CBT remain to be defined. The T cells contained within a CB graft have greater immune tolerance to HLA-mismatching, generally attributed to the overall immaturity of immune cells in the graft. 29, 30 Decreased cytotoxicity of CB CD8 þ T cells, 31, 32 impaired allogeneic activation with subsequent decreased production of IFN-g, 33 defective Th1 responses of CB T cells related to differential expression and activation of transcription factors, 34 and impaired CB DC maturation and cytokine production, 35 compared with adult PB and BM cells, have all been implicated as potentially contributing to the altered immune function of CB cells. The interaction of these differences with the greater degree of HLA-mismatching after CBT as compared with unrelated BMT or PBSCT remains to be determined.
Our study represents a single-center analysis, and the results might not be representative of those at other centers. Moreover, the relatively short follow-up for some of the patients limits our ability to assess the overall duration of and probability of discontinuing systemic treatment and the number of treatment cycles needed to control the disease as related to the different subtypes of GVHD.
In conclusion, our results indicate that the incidence of chronic GVHD by traditional and NIH criteria is not higher than observed after other stem cell sources using better HLA-matched donors at our institution, but the rates are higher than reported at other centers after CBT. The incidence of classic chronic GVHD is low in both adult and pediatric patients after single or dCBT, confirming the findings reported after single CBT in pediatrics. 26 The prevalence of 'late acute' GVHD after CBT and the suggested shorter duration of systemic treatment may indicate that GVHD in this setting may be less protracted and possibly more amenable to treatment.
